Ann: General Meeting Presentation, page-13

No prospect of a midkine deal or Lyramid separation this calendar year - blamed on VC firms not engaging during Covid shutdown. That sounded a bit feeble to me compared to previous optimism and may be why there is a sudden rush towards diagnostics being the new salvation. I'm not sure it's a belief in the opportunity or a hopeful punt, but the claim was it's a result of business enquiries from various markets. I don't infer "partnerships" as anything other than tying up some sales deals.

Confidence remains in online and shopping TV for keeping Evolis ticking over. Priceline is holding off on introducing new products.

Finally, trading will resume when the ASX says so!